Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Julian G. Hurdle"'
Autor:
Abiola O. Olaitan, Chetna Dureja, Madison A. Youngblom, Madeline A. Topf, Wan-Jou Shen, Anne J. Gonzales-Luna, Aditi Deshpande, Kirk E. Hevener, Jane Freeman, Mark H. Wilcox, Kelli L. Palmer, Kevin W. Garey, Caitlin S. Pepperell, Julian G. Hurdle
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decrea
Externí odkaz:
https://doaj.org/article/424d815f462b4e1c9fe133cfb7dbf801
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 2 (2021)
ABSTRACT Ebselen, a reactive organoselenium compound, was shown to inhibit toxins TcdA and TcdB by covalently binding to their cysteine protease domains. It was suggested that ebselen lacked antimicrobial activity against Clostridioides difficile. Ho
Externí odkaz:
https://doaj.org/article/2b0122cbcf7f4fce991449fb0b7fa390
Autor:
Mingming Zhang, Allan M. Prior, Marcus M. Maddox, Wan-Jou Shen, Kirk E. Hevener, David F. Bruhn, Robin B. Lee, Aman P. Singh, Justin Reinicke, Charles J. Simmons, Julian G. Hurdle, Richard E. Lee, Dianqing Sun
Publikováno v:
ACS Omega, Vol 3, Iss 12, Pp 18343-18360 (2018)
Externí odkaz:
https://doaj.org/article/27abe659138b4f32a2e630d0506d1f8f
Publikováno v:
Antibiotics, Vol 11, Iss 2, p 258 (2022)
Antimicrobial resistance to treatments for Clostridioides difficile infection (CDI) poses a significant threat to global health. C. difficile is widely thought to be susceptible to oral vancomycin, which is increasingly the mainstay of CDI treatment.
Externí odkaz:
https://doaj.org/article/638c575b060a42808da420be563e2008
Publikováno v:
Clinical Infectious Diseases.
Publikováno v:
Open Forum Infectious Diseases. 9
Background Use of vancomycin to treat Clostridioides difficile infection (CDI) has increased following recent IDSA/SHEA treatment guideline updates, applying a selection pressure for resistance development. We previously demonstrated acquired mutatio
Autor:
Abiola O. Olaitan, Chetna Dureja, Madison A. Youngblom, Madeline A. Topf, Wan-Jou Shen, Anne J. Gonzales-Luna, Aditi Deshpande, Kirk E. Hevener, Jane Freeman, Mark H. Wilcox, Kelli L. Palmer, Kevin W. Garey, Caitlin S. Pepperell, Julian G. Hurdle
Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decreasing clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5f1ada71740c933e215be5afe7e5271
https://doi.org/10.1101/2022.09.23.509282
https://doi.org/10.1101/2022.09.23.509282
Autor:
Krissada Norseeda, Fahad Bin Aziz Pavel, Jacob T. Rutherford, Humna N. Meer, Chetna Dureja, Julian G. Hurdle, Kirk E. Hevener, Dianqing Sun
Publikováno v:
Bioorganic & Medicinal Chemistry. :117330
Autor:
Ravi K. R. Marreddy, Jonathan Picker, Gregory A. Phelps, Reid Powell, Philip T. Cherian, John J. Bowling, Clifford C. Stephan, Richard E. Lee, Julian G. Hurdle
Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. We investigated the therapeutic potential of inhibiting the biosynthesis of TcdA and TcdB. Accordingly, screening of struc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24ae292774bfbac26706fdaa554e8932
https://doi.org/10.1101/2022.04.20.488993
https://doi.org/10.1101/2022.04.20.488993
Ferrous iron is the dominant form of iron in the oxygen-limited large intestine, the site for Clostridioides difficile infection (CDI). We investigated the extent to which C. difficile requires the ferrous iron transporter 1 (FeoB1), a main permease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1cfeac9088a134bb13e7bc5c4be4f18
https://doi.org/10.1101/2022.03.03.482942
https://doi.org/10.1101/2022.03.03.482942